Sage Therapeutics' Parkinson's drug fails in mid-stage study
17/04/2024 11:39
April 17 (Reuters) - Sage Therapeutics SAGE.O said on Wednesday its experimental drug to treat patients with mild cognitive impairment due to Parkinson's disease failed to show significant improvement in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com))
Recent news on Sage Therapeutics
See all newsBrief: Supernus Pharmaceuticals Completes Acquisition Of Sage Therapeutics
Sage Therapeutics Inc Reports Results For The Quarter Ended June 30: Earnings Summary
SAGE Therapeutics Q2 revenue rises sequentially
Brief: Supernus Pharmaceuticals Announces Expiration Of Hart-Scott-Rodino Waiting Period For Sage Therapeutics Tender Offer
Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview